3D bioprinting for cardiovascular regeneration and pharmacology

Cui, Haitao; Miao, Shida; Esworthy, Timothy; Zhou, Xuan; Lee, Se‐Jun; Liu, Chengyu; Yu, Zu‐Xi; Fisher, John P.; Mohiuddin, Muhammad M.

doi:10.1016/j.addr.2018.07.014

Cited by 140 publications

(146 citation statements)

References 208 publications

(381 reference statements)

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…The bioprinting fabrication process is highly controllable, allowing precise positioning of various biomaterials and living cells simultaneously according to the natural compartments of the target tissue or organ. When compared with traditional tissue engineering techniques, 3D bioprinting offers additional important advantages, such as high precise cell placement and high digital control of speed, resolution, cell concentration, drop volume, and diameter of printed cells [48,49].…”

Section: Bioprinting For Cardiovascular Applicationsmentioning

confidence: 99%

“…Another bioink option is decellularization of allogenic or xenogenic tissues, which contain a variety of proteins, proteoglycans, and glycoproteins [48]. The use of decellularized ECM as bioinks offers the possibility to recreate more complex biologically and biochemically microenvironments, that mimic tissue specific ECM composition or resident cytokines [55].…”

Section: Bioprinting For Cardiovascular Applicationsmentioning

confidence: 99%

“…Nevertheless, during the years, other cell populations different from CMs have been used for brioprinting cardiac tissue models, including embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). The advantages in using these cell types is that most of them is produced pre-clinically and is safe and effective in clinical practice [48]. These works provided the input for the development of scaffold-based 3D bioprinting works ( Figure 6A).…”

Section: Bioprinting Of Functional Myocardiummentioning

confidence: 99%

“…Nevertheless, during the years, other cell populations different from CMs have been used for brioprinting cardiac tissue models, including embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). The advantages in using these cell types is that most of them is produced pre-clinically and is safe and effective in clinical practice [48]. Gaetani and coworkers used the method of pressure-based extrusion to bioprint a patch of human cardiac-derived cardiomyocyte progenitor cells (CMPCs) (30 × 10 6 cells/mL) on a scaffold made from alginate, which was characterized by precise pore size and microstructure [66].…”

Section: Bioprinting Of Functional Myocardiummentioning

confidence: 99%

See 3 more Smart Citations

Recent Applications of Three Dimensional Printing in Cardiovascular Medicine

Gardin

Ferroni

Latrémouille

et al. 2020

Cells

View full text Add to dashboard Cite

Three dimensional (3D) printing, which consists in the conversion of digital images into a 3D physical model, is a promising and versatile field that, over the last decade, has experienced a rapid development in medicine. Cardiovascular medicine, in particular, is one of the fastest growing area for medical 3D printing. In this review, we firstly describe the major steps and the most common technologies used in the 3D printing process, then we present current applications of 3D printing with relevance to the cardiovascular field. The technology is more frequently used for the creation of anatomical 3D models useful for teaching, training, and procedural planning of complex surgical cases, as well as for facilitating communication with patients and their families. However, the most attractive and novel application of 3D printing in the last years is bioprinting, which holds the great potential to solve the ever-increasing crisis of organ shortage. In this review, we then present some of the 3D bioprinting strategies used for fabricating fully functional cardiovascular tissues, including myocardium, heart tissue patches, and heart valves. The implications of 3D bioprinting in drug discovery, development, and delivery systems are also briefly discussed, in terms of in vitro cardiovascular drug toxicity. Finally, we describe some applications of 3D printing in the development and testing of cardiovascular medical devices, and the current regulatory frameworks that apply to manufacturing and commercialization of 3D printed products.Cells 2020, 9, 742 2 of 33 Cells 2020, 9, 742 3 of 33 in digital modeling softwares without the need for file type conversion [16]. Several medical image segmentation softwares are available; some of these are open-source and freely accessible, while others are commercial, licensed products. From the DICOM dataset, the target anatomic geometry is identified and segmented based on properties such as contrast or brightness [17]. As a result, segmentation masks are created such that pixels with the same intensity range are grouped and converted into 3D digital models using rendering techniques. These segmented digital models are then exported out in the standard tessellation language (STL) file type, which is the industry standard for 3D objects and 3D printing software [17]. Nevertheless, STL files do not contain color information and in order to print in multiple colors, a different file format will need to be used. For example, virtual reality modeling language (VRML) and additive manufacturing file format (AMF) provide multiple color and material options [18]. Once segmentation is completed, the final 3D digital model may be further modified within computer-aided design (CAD) software. The main post-processing adjustments of the 3D model are: Repairing errors and discontinuities that sometimes arise in the image segmentation and exporting processes, smoothing of the surface of the model due to scaling errors resulting from the resolution of the original medical image, and addition of other...

show abstract

Section: Bioprinting For Cardiovascular Applicationsmentioning

confidence: 99%

Section: Bioprinting For Cardiovascular Applicationsmentioning

confidence: 99%

Section: Bioprinting Of Functional Myocardiummentioning

confidence: 99%

“…Nevertheless, during the years, other cell populations different from CMs have been used for brioprinting cardiac tissue models, including embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). The advantages in using these cell types is that most of them is produced pre-clinically and is safe and effective in clinical practice [48]. Gaetani and coworkers used the method of pressure-based extrusion to bioprint a patch of human cardiac-derived cardiomyocyte progenitor cells (CMPCs) (30 × 10 6 cells/mL) on a scaffold made from alginate, which was characterized by precise pore size and microstructure [66].…”

Section: Bioprinting Of Functional Myocardiummentioning

confidence: 99%

See 2 more Smart Citations

Recent Applications of Three Dimensional Printing in Cardiovascular Medicine

Gardin

Ferroni

Latrémouille

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…In many cases, the patient will not survive long enough to receive a donor heart [68,69]-and the need for a readily available heart substitute is very real. Perhaps due to the urgent nature of this clinical condition, the application of 3D bioprinting in the cardiovascular domain has seen rapid progress in recent years.…”

Section: Cardiovascular Tissuementioning

confidence: 99%

Clinical Perspectives on 3D Bioprinting Paradigms for Regenerative Medicine

Loai¹,

Kingston²,

Wang³

et al. 2019

Regen Med Front.

View full text Add to dashboard Cite

Three-dimensional (3D) bioprinting is an emerging manufacturing technology that layers living cells and biocompatible natural or synthetic materials to build complex, functional living tissue with the requisite 3D geometries. This technology holds tremendous promise across a plethora of applications as diverse as regenerative medicine, pathophysiological studies, and drug testing. Despite some success demonstrated in early attempts to recreate complex tissue structures, however, the field of bioprinting is very much in its infancy. There are a variety of challenges to building viable, functional, and lasting 3D structures, not the least of which is translation from a research to a clinical setting. In this review, the current translational status of 3D bioprinting is assessed for several major tissue types in the body (skin, bone/cartilage, cardiovascular, central/peripheral nervous systems, skeletal muscle, kidney, and liver), recent breakthroughs and current challenges are highlighted, and future prospects for this exciting research field are discussed. We begin with an overview of the technology itself, followed by a detailed discussion of the current approaches relevant for bioprinting different tissues for regenerative medicine.

show abstract